# 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

> **NCT02107196** · PHASE3 · COMPLETED · sponsor: **Menarini Group** · enrollment: 535 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Diarrhea

## Interventions

- **DRUG:** Ibodutant 10 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02107196
- **Lead sponsor:** Menarini Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 535 (ACTUAL)
- **Last updated:** 2017-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02107196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02107196, "12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02107196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*